Skip to main content

AG Barr Seeks DOJ Facebook Antitrust Probe, Despite the Already Launched FTC Inquiry

The Justice Department intends to investigate Facebook after prodding from U.S. Attorney General William Barr, according to a person familiar with the matter, even though the Federal Trade Commission already has an inquiry underway.

The social-media giant now faces parallel probes by two federal agencies over whether it has harmed competition in violation of antitrust laws.

The Justice Department’s case will focus on conduct that’s separate from what the FTC is examining, said the person, who declined to be named because the matter is confidential. The two federal inquiries are in addition to investigations by state attorneys general and the House Judiciary Committee.

The simultaneous Facebook probes are a departure from the agencies’ usual practice of dividing up scrutiny of companies based on staff expertise. They share antitrust enforcement power and often hammer out so-called clearance agreements, some of which can involve considerable behind-the-scenes wrangling, to avoid overlap.

The FTC began its investigation of Facebook after striking an agreement in May with the Justice Department to divide four of the biggest tech companies between them. Under that deal, the FTC got jurisdiction over Facebook and Amazon while the Justice Department’s antitrust division took Alphabet’s Google and Apple.

That agreement has now been overridden after Barr pushed to retain jurisdiction over Facebook, the person said. The agreement with the FTC didn’t cover all conduct by the four companies, according to two people familiar with the matter. The Justice Department could also look at some of Amazon’s business practices, one of the people said.

Justice Department officials feel obliged to carry out the department’s mandate to enforce the antitrust laws, especially given the widespread concerns over tech platforms, according to a third person familiar with the matter.

FTC Chairman Joe Simons believes the Justice Department is infringing on its territory and wrote a letter to the department about the issue, according to one of the people. The Justice Department responded with its own letter, another person said. The FTC’s letter was previously reported by the Wall Street Journal.

The FTC and Facebook declined to comment. 

Signs of the Justice Department’s interest in Facebook first emerged publicly at the end of July, when it announced a broad review of large technology platforms. While the department said it was looking at “social media,” it didn’t specify any companies. Facebook disclosed that investigation to investors a few days later, without specifying whether it was a target.

That July announcement followed a meeting between the FTC’s Simons and top Justice Department officials, including Barr, who expressed interest in looking at Facebook conduct, said the person.

By then, the FTC was already forging ahead with its Facebook case. The agency is looking at social media, digital advertising and mobile applications, according to a Facebook disclosure. 

The jurisdictional dispute spilled into public view last week during an oversight hearing on Capitol Hill. Republican Senator Mike Lee of Utah told Makan Delrahim, the Justice Department’s antitrust chief, and the FTC’s Simons that he was concerned about how they were dividing scrutiny of the tech companies.

“It sounds like your agencies may be pursuing monopolization investigations of the same companies at the same time,” he said. “Now, let me be clear, I don’t think your agencies should be divvying up parts of a monopolization investigation of the same company — tech company or, otherwise.”

Both Simons and Delrahim acknowledged that there had been disagreements.

“I cannot deny there are instances where Chairman Simons’ and my time is wasted on those types of squabbles,” Delrahim said.

More must-read stories from Fortune:

—The cheapest mobile plans for your iPhone 11
—What is quantum supremacy, and why is it such a computing milestone?
Beyoncé was sued for violating the Americans with Disabilities Act. And you could be, too
—Meet the women leading Netflix into the streaming wars
—Why Discord is one of tech’s hottest startups
Catch up with Data Sheet, Fortune’s daily digest on the business of tech.



from Fortune https://ift.tt/2lE1Pru

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be